Compare Merck & Co., Inc. (MRK) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ProShares Ultra Gold ETF — how do they compare? Merck & Co., Inc. trades at $133.6 (market cap $321.77B), while ProShares Ultra Gold ETF trades at $52.28. The key difference: Merck & Co., Inc. pays a 2.61% dividend while ProShares Ultra Gold ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| MRK | UGL | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $131.84 | $85.62 |
52-Week Low | $77.60 | $34.37 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
UGL is trading at $52.13, up 0.81% on the day, with a bullish technical signal from moving averages but overbought conditions indicated by RSI readings above 76. The stock faces immediate resistance at $52-$53 levels while finding support around $51. Recent gold market strength driven by inflation data and Fed policy expectations provides positive sector momentum.
The stock shows technical strength but requires fundamental validation through earnings reports and financial metrics. Key risks include gold price volatility and Fed policy sensitivity. Investors should monitor upcoming financial disclosures for confirmation of the current technical bullishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
